Navigation Links
American Oriental Bioengineering to Announce First Quarter 2011 Financial Results on May 9, 2011
Date:5/6/2011

NEW YORK, May 6, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that it plans to release first quarter 2011 financial results on Monday, May 9, 2011, after the market closes.  

The Company will hold a conference call at 8:00 am ET on Tuesday, May 10, 2011, to discuss its results.  Listeners may access the call by dialing 1-877-299-4454 or 1-617-597-5447 for international callers, access code: 91826695.  A webcast will also be available through AOB's website at www.bioaobo.com.

A replay of the call will be available through May 17, 2011.  Listeners may access the replay by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 86841058.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.  

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995.  Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements.  The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking
'/>"/>

SOURCE American Oriental Bioengineering, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Aspirin Named 8th World Wonder by Majority of Americans
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
8. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
9. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Oncobiologics, Inc., a biotherapeutics company ... biosimilars, has completed the construction of its GMP ... Cranbury, New Jersey . ... is designed to utilize multiple technologies that enable ... Through the use of the latest single-use technologies, ...
(Date:5/4/2015)... May 4, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of advanced ... Godshall , is scheduled to present at the Bank of ... Las Vegas on Thursday, May 14, 2015, at ... webcast of the Company,s presentation at the conference will be ...
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 ... Lilly and Company (NYSE: LLY ) and ... positive results from DURATION-2, the second in a series ... once weekly, an investigational diabetes therapy, as compared to ...
... new study, published in the Journal of Medicinal ... 8 grams (1/3 ounce) of "Sun Chlorella A" daily ... total cholesterol, and fasting blood glucose levels.For a 12-week ... A" tablets each morning and evening. Seventeen subjects ...
Cached Medicine Technology:Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 2Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 3Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 4Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 5Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study 6First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... Food and Drug Administration (FDA) have approved the drug Femara ... breast cancer among post menopausal women//. ,Various studies ... result of these studies was published in the December 29 ... said that the Novartis drug Femara was very efficient in ...
... of swallows in Malawi had raised fears about the possibility of ... // have revealed a negative bird flu infection status of ... ,"We have tested samples that were sent to us ... swallows, which were dying in large numbers. We don't know what ...
... enterotoxin produced by the bacteria Vibrio cholerae, which leads to ... has occurred in two cities in // ... infected with the bacteria in two districts of Chikomba and ... is high in conditions where treatment is not given. The ...
... in attitudes toward circumcision in Swaziland, which has one of ... one of the highest HIV prevalence rates. ... sudden comeback in the country since the publication of a ... risk of contracting HIV. ,According to the ...
... children is a major health hazard. More-so when homes use ... lead // poisonings in children, by suggesting new requirements ... years, Lead, a highly toxic metal has been used as ... spectrum of health problems ranging from cognitive impairment and learning ...
... Kerr has urged to increase awareness of organ donation among ... loss dying // due to organ failure and non-availability ... heavy human loss of young people and their lives depend ... Donor cards and registration with NHS organ donor register, which ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Child-friendly initiative For Lead-Based Paint Work: EPA, USA 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: